PanTheryx Aims to End Diarrheal Disease in Cambodia

Company launches new efforts through its Equity of Access Initiative to reduce the burden of pediatric infectious diarrhea on the poorest and hardest to reach children in Cambodia.

BOULDER, Colo.–(BUSINESS WIRE)–PanTheryx, a U.S. biotechnology company focused on addressing serious GI-related health conditions, announced today a new partnership with Zuellig Pharma, a leading healthcare company in Asia, and Project C.U.R.E., the world’s largest provider of donated medical supplies and equipment in developing countries, to help end pediatric infectious diarrhea in Cambodia. The partnership was developed through PanTheryx’s Equity of Access Initiative, which was created to alleviate the burden of pediatric infectious diarrhea on the poorest and hardest to reach communities around the world.

Diarrhea is a leading killer of children, accounting for approximately 8 percent of deaths under age five worldwide. In Cambodia, pediatric diarrhea is reported as the second leading cause of death in children under five. Many of these deaths could be avoided if access to proven prevention and management interventions were made routinely available to all Cambodian children.

PanTheryx’s Equity of Access Initiative provides diarrhea prevention and treatment education, access to PanTheryx’s breakthrough anti-diarrheal nutritional product, DiaResQ, and other medical supplies needed in underserved rural and low-income populations who are most susceptible to diarrheal disease.

In partnership with Zuellig Pharma, Pantheryx will donate 12,000 doses of DiaResQ to the National Pediatric Hospital, a government-run hospital located in Phnom Penh and managed by the Ministry of Health. To reach rural areas where diarrhea can be even more life threatening, PanTheryx is partnering with Project C.U.R.E. Along with product and supplies, they will provide education on diarrhea management to select clinics and healthcare workers in Siem Reap, one of the poorest provinces in the country.

“I could not be more proud of the work we are doing in Cambodia,” said Mark Braman, CEO of PanTheryx. “Working toward a greater good and keeping our mission at the forefront of everything we do is what fuels new opportunities, forward movement, and invites collaboration with partners like Zuellig Pharma and Project C.U.R.E. To work with partners who share a vision of a world where everyone has access to healthcare, not just those who can afford to buy it, is truly inspirational.”

“Over the last five years, our partnership with PanTheryx has touched thousands of people’s lives through the distribution of the DiaResQ product and our training of nurses, doctors and community health workers,” said Douglas Jackson, President and CEO of Project C.U.R.E. “This new initiative in Cambodia is a nexus of several leading health organizations. Together we will address the needs of the local communities and empower the resident health professionals to meet the Sustainable Development Goals in their villages and cities.”

About PanTheryx

PanTheryx is a biotechnology company committed to realizing the potential of novel interventions to address a wide range of serious GI microbiome related health conditions. The company creates first-in-class therapeutics, with products developed from its patented technology platform spanning the range of nutritional interventions to biologics. PanTheryx is also the premier supplier of bovine colostrum, which has extensive applications in health and wellness, including GI health. Founded in 2007, PanTheryx is headquartered in Boulder, Colorado and has production facilities in Phoenix, AZ and Ripon, CA. For more information, please visit PanTheryx.com.

About Project C.U.R.E.

Established in 1987, Project C.U.R.E. is the largest provider of donated medical supplies and equipment to developing countries around the world. Currently, Project C.U.R.E. maintains large distribution warehouses in Arizona, Colorado, Illinois, Texas, Pennsylvania and Tennessee, and smaller collection centers in nine U.S. cities. Because of the dedication of more than 25,000 nationwide volunteers, three to four 40-foot cargo containers of life-saving medical aid leave Project C.U.R.E.’s warehouses each week. Project C.U.R.E. has reached patients, families and children in more than 130 countries. Project C.U.R.E. is the recipient of the GuideStar Exchange Silver Seal, the Charity Navigator Four-Star Rating and has been ranked by Forbes as one of the 20 Most Efficient Large U.S. Charities. Learn more at www.projectcure.org.

About Zuellig Pharma

Zuellig Pharma is one of the largest healthcare services groups in Asia, driven by the purpose of making healthcare more accessible, providing world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with over 10,000 employees. Its people serve over 350,000 medical facilities and work with over 1,000 clients, including the top 20 pharmaceutical companies in the world.

More recently, Zuellig Pharma has launched its Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, its teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.

Contacts

Holly Potter, Director

+1 303.951.6883

[email protected]